Dr. Diego Marra is a Board-Certified Dermatologist and Fellowship-Trained Mohs Surgeon in Fort Worth and Grapevine, Texas.
One of U.S. Dermatology’s Mohs Surgery specialists, Dr. Diego Marra graduated summa cum laude with a Bachelor of Arts degree with special honors in Zoology from the University of Texas. He received his medical training at the Harvard Medical School and the Harvard-MIT Program in Health Sciences and Technology, graduating magna cum laude with special honors in Vascular Biology.
Following medical school, Dr. Diego Marra obtained special training in Mohs micrographic, cutaneous laser, and cosmetic surgery. He was awarded a fellowship at the Ronald L. Moy Surgery Center in Los Angeles and is accredited by the American College of Mohs Micrographic Surgery, the American Academy of Cosmetic Surgery, and the Accreditation Council for Graduate Medical Education. He completed his residency in dermatology at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts.
A diplomate of the American Board of Dermatology, Dr. Diego Marra is the author of peer-reviewed original research published in some of the leading journals in the fields of dermatology and dermatologic surgery, including Archives of Dermatology, Journal of the American Academy of Dermatology, American Journal of Cosmetic Surgery, and Dermatologic Surgery. His work has been presented at major specialty meetings across the country and internationally.
2801 S Hulen St
Fort Worth, TX 76109
Actinic Keratosis, also known as solar keratosis, is a scaly or crusty lesion on the skin that develops slowly and indicates the presence of sun damage. It is most commonly found on parts of the body frequently exposed to the sun including the bald scalp, face, ears, lips, backs of the hands or forearms, neck, and shoulders.
Actinic keratoses are considered precancerous and can develop into a type of skin cancer called squamous cell carcinoma. In fact, some 40 to 60 percent of squamous cell skin cancers begin as untreated actinic keratoses.
Because of this, your doctor should be diligent in diagnosing, treating and monitoring actinic keratosis.
Basal Cell Carcinoma, also known as basalioma or basal cell cancer, is the most common type of skin cancer and carries the least amount of risk, though it still requires attention. If caught and treated early, basal cell carcinomas are not likely to be life-threatening, but they do have the potential to cause disfigurement of the skin tissue.
Almost one million new cases of basal cell carcinoma are diagnosed each year in the U.S., and up to 30% of Caucasians may develop basal cell carcinomas in their lifetime.
Skin cancer is considered low risk when the affected cells remain clustered in a single group. Both basal cell carcinoma and squamous cell carcinoma are rarely life-threatening. Though it is unlikely to spread to other parts of your body, if left untreated, basal cell carcinoma can move into nearby bone or other tissue.
Basal cell carcinoma typically begins as a small, shiny bump on the face, although it can occur on any part of the body.
Cryotherapy, or “cryosurgery,” is a simple, non-invasive procedure in which liquid nitrogen is used to freeze and destroy growths on the surface of the skin. This is an effective treatment for precancerous skin lesions (actinic keratoses), as well as other skin conditions such as warts, skin tags and moles.
Applying liquid nitrogen to skin lesions allows dermatologists to target the damaged skin cells and destroy them at the cellular level. After freezing, the affected area may blister and scab over, and should heal within three to six weeks.
Our dermatology team uses cryosurgery to treat a wide range of conditions. It offers a number of advantages: Cryotherapy is a simple, affordable outpatient procedure, the discomfort level is minimal, and there is a low risk of infection.
Melanoma, the deadliest of skin cancers, only accounts for about 4 percent of all skin cancer cases, but causes about 79 percent of skin cancer deaths.
Melanoma is a cancer of the skin that begins in the melanocytes, which are the cells that produce the pigment melanin. It is the leading cause of cancer death in women 25 to 30 years old and the second leading cause of cancer death in women 30 to 35 years old.
In some cases, melanoma occurs in melanocytes throughout the body, even if those parts have never been exposed to the sun.
Mohs surgery offers the highest cure rates for all non-melanoma skin cancers. For certain cases of the most common types of skin cancer — squamous cell carcinoma and basal cell carcinoma — the cure rate can be as high as 99 percent.
Mohs surgery is a highly specialized surgical technique used to treat non-melanoma skin cancers in which the surgeon removes all of the visible cancer, plus a small margin of the surrounding healthy tissue and examines it to ensure that all cancer cells have been removed at the time of surgery.
During Mohs micrographic surgery — named after Dr. Frederic Mohs, who first performed it in the 1930s — cancer is removed from the skin layer by layer until all cancerous cells have been removed. This type of surgery is most commonly used for cancers that have a high risk of re-occurrence. This technique allows for complete removal of the skin cancer while minimizing the removal of surrounding healthy skin.
A rare and aggressive form of skin cancer, sebaceous carcinoma is sometimes referred to as sebaceous gland carcinoma, sebaceous gland adenocarcinoma or meibomian gland carcinoma.
Sebaceous carcinoma can develop in any sebaceous glands, which lubricate the skin, but it most often begins on or around the eyelids. If it is found and treated early, treatment is often successful. However, if sebaceous carcinoma spreads, it can be deadly.
Because sebaceous carcinoma can appear to be a benign growth such as a stye, diagnosis is often delayed, which increases the risk of death. If you notice a growth on your eyelid, it’s important to make an appointment with your dermatologist. The sooner sebaceous carcinoma is diagnosed and treated, the better the outcome.
Skin cancer is the most common form of cancer in the U.S. with more than 3.5 million cases diagnosed each year.
Skin cancer is the result of uncontrolled growth of abnormal skin cells that takes place when skin cells suffer DNA damage and then mutate, causing them to multiply rapidly and form malignant (cancerous) tumors. Most skin cancers develop on the visible outer layer of the skin (the epidermis), particularly on sun-exposed areas such as the face, head, hands, arms and legs. They are usually easy to detect with a skin examination, which increases the chances of early diagnosis.
There are different types of skin cancer, each named for the type of skin cell from which they originate. The most common type of skin cancer is basal cell carcinoma. Almost one million new cases of basal cell carcinoma are diagnosed each year in the U.S. Most skin cancers fall into one of three categories:
There are often warning signs that cancer is developing. The most common are pre-cancerous lesions called actinic keratoses that often develop on sun-exposed areas. These tumors replace normal surrounding tissue and generally do not spread to other areas.
Skin cancer is considered low risk when the affected cells remain clustered in a single group. Both basal cell carcinoma and squamous cell carcinoma are rarely life-threatening.
Skin cancer is considered a high risk when cells have invaded surrounding tissues. The third most common skin cancer, malignant melanoma, can be life-threatening if not diagnosed and treated early.
If skin cancer is detected before it has spread to surrounding tissues, the chances of a complete recovery and cure are excellent. High-risk forms of cancer like melanoma require more aggressive treatments.
Squamous Cell Carcinoma is a common form of skin cancer that develops in the squamous cells that make up the outer layer of the skin. Although it is usually not life-threatening, it can be aggressive in some cases.
If left untreated, squamous cell carcinoma can grow large or spread to other parts of your body, causing serious complications.
If you’ve noticed new skin growths, lumps, or bumps, chances are you’re dealing with a lesion. But, to know whether or not the lesion is benign, you’ll need to consult with a professional. At U.S. Dermatology Partners, our skilled dermatologists can partner with you to determine the type of lesion and help you decide if treatment is necessary for your condition. To get started, simply fill out our online scheduling request form, and a U.S. Dermatology Partners team member will be in touch to finalize the details of your visit.
Benign lesion is an umbrella term that may reference any number of non-cancerous lesions of the skin. These lesions may develop on any part of the body with soft tissue. They are classified (named) according to their specific sets of features, where they develop, and other characteristics. Determining if a lesion is non-cancerous requires an accurate diagnosis from a dermatologist.
Atypical moles, also known as dysplastic nevi, are unusual-looking benign (noncancerous) moles.
A dysplastic mole is one that, when viewed on a cellular level, has features unlike those of a healthy, benign mole. A benign mole will have a regular pattern of coloration and pigment, even borders, symmetry, and a tan or pink color. Dysplastic moles can be asymmetric, have indistinct borders, or contain multiple colors or very dark pigment.
Dysplastic moles are often spotted as the “ugly duckling” on a patient’s skin. Any departure from the typical mole a person’s skin makes may be dysplastic. They can appear anywhere on the body, but in most cases are found on the back, chest, buttocks, breasts, or scalp.
The sun can age and burn your skin, and it can also cause damage on the cellular level, leading to skin cancer. The good news is, the U.S. Dermatology Partners team can help you formulate a plan to prevent sun damage and repair the effects of the sun’s UV rays so that you can go out and enjoy a sunny day. Learn more on this page or contact U.S. Dermatology Partners to schedule an appointment with us.